Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal-Reference-Cited by-同舟云学术

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Published:2017-05 Issue:5 Volume:28 Page:1036-1041
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ott P.A.,Piha-Paul S.A.,Munster P.,Pishvaian M.J.,van Brummelen E.M.J.,Cohen R.B.,Gomez-Roca C.,Ejadi S.,Stein M.,Chan E.,Simonelli M.,Morosky A.,Saraf S.,Emancipator K.,Koshiji M.,Bennouna J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/5/1036/24169345/mdx029.pdf

Reference31 articles.

1. The epidemiology of anal cancer;Grulich;Sex Heal,2012

2. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis;De Vuyst;Int J Cancer,2009

3. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.

4. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study;Flam;J Clin Oncol,1996

5. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial;Ajani;JAMA,2008

Cited by 210 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-Analysis;2024-07-03

2. Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance;Current Oncology Reports;2024-06-11

3. Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan;International Journal of Clinical Oncology;2024-05-31

4. Prognostic value of PD-L1 expression in patients with anal cancer: a meta-analysis;Biomarkers in Medicine;2024-04-02

5. Progress in the treatment of anal cancer: an overview of the latest investigational drugs;Expert Opinion on Investigational Drugs;2024-01-30